|Videos|July 17, 2017
FDA Approval in ALL, Priority Reviews in CML and Breast Cancer, and More
Advertisement
Gina Columbus reports on an FDA approval in acute lymphoblastic leukemia, priority reviews in chronic myeloid leukemia and breast cancer, ODAC recommendations in ALL and and acute myeloid leukemia, and a clinical hold on 3 multiple myeloma trials.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma
2
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
3
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
4
Dr Riedell on the Long-Term Efficacy of Tisa-Cel in R/R Follicular Lymphoma
5
































